Bayesian Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Bayesian Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-24,715	Closed	-$1.62M	–	326
2025 Q3	$1.62M	Buy	24,715 +8,115	+49%	+$396K	0.33%	92
2025 Q2	$656K	Buy	16,600 +8,100	+95%	+$265K	0.1%	243
2025 Q1	$256K	Buy	+8,500	New	+$278K	0.04%	432
2023 Q2	–	Sell	-21,227	Closed	-$759K	–	929
2023 Q1	$759K	Buy	+21,227	New	+$797K	0.09%	284
2022 Q3	–	Sell	-9,063	Closed	-$336K	–	854
2022 Q2	$336K	Buy	+9,063	New	+$342K	0.06%	437
2020 Q2	–	Sell	-5,300	Closed	-$251K	–	639
2020 Q1	$251K	Buy	5,300 +1,815	+52%	+$101K	0.05%	520
2019 Q4	$211K	Buy	+3,485	New	+$208K	0.04%	523
2017 Q1	–	Sell	-10,138	Closed	-$485K	–	543
2016 Q4	$485K	Buy	+10,138	New	+$401K	0.12%	314

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bayesian Capital Management's IONS Position: Q4 2025 in Review

Bayesian Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2025, closing a stake of 24,715 shares — an estimated $1.62M sold.

Bayesian Capital Management first reported a position in IONS in Q4 2016 and held it in 8 quarters. The position peaked at $1.62M in Q3 2025. 491 funds tracked by Wall St. Rank hold IONS as of Q4 2025.

Bayesian Capital Management reported no remaining Ionis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Bayesian Capital Management sold 24,715 Ionis Pharmaceuticals shares in Q4 2025, an estimated $1.62M.
Bayesian Capital Management first reported a position in Ionis Pharmaceuticals in Q4 2016 and held it in 8 quarters.
Bayesian Capital Management's Ionis Pharmaceuticals position peaked at $1.62M in Q3 2025.
491 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2025.

Based on Bayesian Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.